Australia | Apr 11 2006
FN Arena’s severely under-resourced healthcare and biotech reporting desk is having a hard time these days. Luckily we can fall back on the efforts of ABN Amro Morgans’ sector specialists Tanya Solomon and Scott Power every once in a while.
Solomon and Scott’s latest sector update would suggest there are lots of positive developments occurring in the sector – if only investors would not be so focused on finding that remaining undiscovered gold or copper explorer.
The first positive event cited in the analysts’ weekly sector update is Alchemia (ACL) announcing it is in an advanced stage of negotiating a collaboration agreement with an international pharmaceutical company.
Solomon and Power like Alchemia, that’s why they have a Buy recommendation on the stock in the first place. They probably like the stock even more now as the negotiations have kicked in sooner than they anticipated thus far.
Both have initiated coverage on Avexa (AVX) during the week and that turned out positively as well as the microcap received a maiden Buy recommendation with a target of $0.73, more than double at what the shares are currently trading at.
Somnomed (SOM) – try to say that out loud five times in a row – opened a US office and both analysts believe this is a positive as well. Of more importance is that Evogenix (EGX) has "in-licensed" an anti-cancer antibody from the University of Massachusetts Medical School. Again, Solomon and Scott argue this is much quicker than they thought it would happen. Positive.
Solomon and Scott have also added a list of some things to look forward to. Peplin (PEP), rated Buy with a twelve month price target of $0.87 is expected to announce the first of two clinical trial results for PEP005 Topical for Basal Cell Carcinoma in the first week of May, the analysts believe.
Cytopia (CYT) has already flagged a licensing deal for one of its drug programs that could be announced anytime soon. Both analysts note that a climbing share price and increasing trading volumes reinforce their expectation a deal could be close.
And lastly, there’s artificial heart company Ventracor (VCR). Yes, it’s rated Buy as well with a price target of $1.64. The company’s US feasibility trial recruitment is expected to be finished within four weeks. In addition, the company’s rights issue closes on 11 April 06.

